Immuno-therapy cancer drug, it is made up of antibodies that boosts the body’s ability to trigger an anti-tumour response that helps it attack cancer cells. It has been approved to treat many types of cancer, including non-small cell lung, classical Hodgkin lymphoma, melanoma, gastric and cervical cancer In 2019, Merck announced plans to fast track the use of Keytruda to treat prostate and head and neck cancer. Trials have shown a 44% reduction in risk of death or the disease worsening with Keytruda. Contact us today and learn about the drug dosage and various cancers that can be treated with this drug.
Keytruda (pembrolizumab) is a medication used for the treatment of advanced melanoma, metastatic nonsquamous NSCLC, recurrent or metastatic Head and Neck Squamous Cell Carcinoma (HNSCC), recurrent classical Hodgkin Lymphoma (cHL), locally advanced or metastatic urothelial carcinoma, solid tumours having the biomarkers MSI-H or dMMR, recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
|Oncology||Urothelial Carcinoma, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Lymphoma, Skin Cancer|
|Mode of Action||Monoclonal antibody (immunotherapy)|
|Regulatory agency approval||European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia|